Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 202 JPY Market Closed
Market Cap: 18.2B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Cash Taxes Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Healios KK
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Cash Taxes Paid
ÂĄ4m
CAGR 3-Years
-13%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Cash Taxes Paid
ÂĄ2.3B
CAGR 3-Years
48%
CAGR 5-Years
67%
CAGR 10-Years
49%
PeptiDream Inc
TSE:4587
Cash Taxes Paid
ÂĄ2.2B
CAGR 3-Years
-3%
CAGR 5-Years
15%
CAGR 10-Years
44%
Takara Bio Inc
TSE:4974
Cash Taxes Paid
ÂĄ2.2B
CAGR 3-Years
-21%
CAGR 5-Years
14%
CAGR 10-Years
11%
Pharma Foods International Co Ltd
TSE:2929
Cash Taxes Paid
ÂĄ685m
CAGR 3-Years
45%
CAGR 5-Years
49%
CAGR 10-Years
67%
C
Cuorips Inc
TSE:4894
Cash Taxes Paid
ÂĄ2.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
18.2B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
129.63 JPY
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Healios KK's Cash Taxes Paid?
Cash Taxes Paid
4m JPY

Based on the financial report for Sep 30, 2024, Healios KK's Cash Taxes Paid amounts to 4m JPY.

What is Healios KK's Cash Taxes Paid growth rate?
Cash Taxes Paid CAGR 5Y
-4%

Over the last year, the Cash Taxes Paid growth was -50%. The average annual Cash Taxes Paid growth rates for Healios KK have been -13% over the past three years , -4% over the past five years .

Back to Top